Alcon stock: analysis & valuation

ALC.SWMedical Instruments & SuppliesSwitzerlandData as of Nov 15, 2026
Metrics analysis · Medical Instruments & Supplies

Alcon ALC.SW

Price 61.36 CHF +1.79%Market cap 29.5 bn CHF52 weeks 47.80 – 68.34
Forward P/E
17.0x
Industry 18.5x
EV/EBITDA
16.2x
Industry 15.7x
Revenue growth
4.7%
Industry 4.7%
Operating margin
12.9%
Industry 12.9%
Return on equity
3.0%
Industry 6.3%
Free cash flow yield
3.6%
Industry 3.4%

What does Alcon do?

Alcon is a medical technology company specializing in eye care, based in Switzerland. It develops, manufactures and sells products for eye surgery as well as for vision correction and eye health. The business is divided into two segments: Surgical and Vision Care.

In the Surgical segment, Alcon earns money with devices, diagnostics and visualization systems for cataract and retinal surgery, with intraocular lenses and other implants, and with consumables that are needed on a recurring basis. Customers are mainly clinics and eye surgeons. Vision Care comprises contact lenses and eye care products such as lubricating drops, which are sold through opticians, distributors and retail. Alcon is among the world's largest eye care providers, with a strong market position in cataract surgery. Competitors include Johnson & Johnson Vision, Bausch + Lomb, Zeiss and CooperVision.

Score profile

Quality4.7
Valuation5.0
Growth6.2
Financial strength6.0
Momentum7.4

Rank vs. Medical Instruments & Supplies (28 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Alcon ranks in the middle in the group Medical Instruments & Supplies (4.7/10). On growth, the company ranks above average in the group Medical Instruments & Supplies (6.2/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Instruments & Supplies (5.0/10). On financial strength, Alcon ranks above average in the group Medical Instruments & Supplies (6.0/10).

MetricStockGroup medianRanking
Forward P/E17.0x18.5xbetter than 63 %
Trailing P/E56.3x34.2xbetter than 20 %
PEG ratio1.3x1.3xbetter than 52 %
EV/EBITDA16.2x15.7xbetter than 43 %
Price/sales3.2x3.1xbetter than 41 %
Price/book1.7x2.8xbetter than 83 %
Revenue growth4.7%4.7%better than 50 %
Earnings growth12.5%0.0%better than 73 %
Gross margin57.9%54.7%better than 55 %
Operating margin12.9%12.9%better than 54 %
Net margin6.1%8.5%better than 41 %
Return on equity3.0%6.3%better than 38 %
Debt/equity24.6%36.0%better than 63 %
Current ratio2.5x2.3xbetter than 65 %
Free cash flow yield3.6%3.4%better than 52 %
Dividend yield0.5%0.9%–
Payout ratio25.6%38.9%–
Beta0.720.85–

Valuation: what is Alcon worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Alcon a model range of 43.62 CHF to 70.25 CHF per share.

Price 61.36 CHF
Analysts 73.96 CHF
Fair value range 43.62 CHF – 70.25 CHFMidpoint 59.36 CHF (−3.3% vs. price)

17 analysts, average rating “Buy”, average price target 73.96 CHF (+20.5%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Demand for cataract surgery is rising structurally with population aging and growing access to eye care.
  • Installed devices generate recurring revenue from consumables and implants, which stabilizes sales.
  • Innovations in premium lenses and contact lenses allow for higher prices and strengthen the market position against competitors.

Risks

  • Competitors with comparable products and price pressure can weigh on market share and margins in the lens and contact lens business.
  • Regulatory requirements and approval procedures for medical devices can delay market launches and increase costs.
  • Exchange rate fluctuations and weaker consumer sentiment for self-paid premium procedures can affect revenue and earnings.

What to look for with Alcon

The operating margin is informative, as it shows how well Alcon translates pricing power, product mix and research and sales costs into profitable growth.

Full AI analysis of Alcon

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Alcon stock

What is the P/E ratio of Alcon stock?

Based on expected earnings, Alcon trades at a P/E of 17.0x, compared with a median of 18.5x for the peer group Medical Instruments & Supplies. Based on the earnings of the last twelve months it is 56.3x. (data as of Nov 15, 2026)

Does Alcon pay a dividend?

Yes. The dividend yield is currently 0.5%, with a payout ratio of 25.6% of earnings.

Is Alcon stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Alcon is currently valued roughly in line with the average of the companies in the group Medical Instruments & Supplies (valuation score 5.0 out of 10). Our model calculations (DCF and industry multiples) give a range of 43.62 CHF to 70.25 CHF per share at a price of 61.36 CHF. This is a model calculation, not an investment recommendation.

What do analysts say about Alcon stock?

17 analysts have an average price target of 73.96 CHF (+20.5% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.